New Drug Pipeline

Charis1000, C1K

C1K : TNBC Anticancer Drug


Cancer refers to an uncontrollable abnormal growth of cells. Treatment of cancer cells becomes more important because they ignore normal regulatory functions and continue to multiply through tissue infiltration and metastasis to destroy normal cells and organs and eventually result in death.

Existing cancer treatments include surgical tumor removal, radiation therapy, chemotherapy, and immunotherapy, and these methods are used alone or in combination. A side effect of chemotherapy to remove cancer cells includes remarkably declined quality of patient’s life and low survival rate. Because the patient dies with the attempt to kill cancer cells and it is virtually impossible to remove all cancer cells by conventional methods, we sought to develop a treatment method that effectively removes cancer cells with fewer side effects.

Triple negative breast cancer (TNBC) is a kind of breast cancer with no female hormone (estrogen • progesterone) receptor and HER2 protein, and accounts for approximately 20% of all breast cancer patients. Because existing breast cancer treatments such as hormone therapy and targeted therapy have no effect on TNBC, chemotherapy is mostly used. However, recurrence and metastasis, development of TNBC drug is necessary. However, it frequently develops into recurrence and metastasis after treatment and has poor prognosis that the development of Drug is urgently needed.